The One Biologic He Actually Qualifies For: Severe Asthma With Nothing Elevated
A patient whose eosinophils and exhaled nitric oxide are both unremarkable, leaving exactly one biologic mechanism he is eligible for and real uncertainty about how well it will actually work at his numbers.
Colin B. services wind turbines off the coast, a job that means two-week rotations offshore followed by two weeks fully home, and an asthma history that has made the offshore half increasingly difficult to justify to his employer’s medical office. He has had four exacerbations requiring oral steroids in the past year despite high-dose inhaled corticosteroid, long-acting beta-agonist, and a long-acting muscarinic antagonist all maximized — a burden that would ordinarily put him near the front of the line for a biologic. His biomarker panel does not cooperate. Blood eosinophils have run 80/µL on repeat testing, FeNO sits at 18 ppb, and formal skin testing came back negative across every common aeroallergen panel his allergist ran.
That combination closes off every other biologic mechanism on the market. Anti-IgE requires allergic sensitization he does not have. Anti-IL5/5Rα and anti-IL4Rα both have eosinophil or biomarker floors his numbers do not clear. Tezepelumab is the one exception — NAVIGATOR enrolled patients across the full biomarker spectrum specifically to test whether TSLP inhibition works independent of a type-2-high signature, and it did show real benefit even at low BEC and low FeNO. In NAVIGATOR alone that came to a 39% exacerbation reduction below 150 eosinophils. The finer subgroup numbers come from the pooled PATHWAY-plus-NAVIGATOR analysis rather than NAVIGATOR by itself, and they are honest about how the benefit narrows as biomarkers drop: 48% below 150 eosinophils, holding up on its own; but in the specific combination of low BEC AND low FeNO together — the profile closest to Colin’s — the reduction was 37%, with a confidence interval whose upper bound landed on 1.00 rather than sitting cleanly away from it.
Reviewing a biomarker panel with nothing elevated on it
He is eligible for exactly one biologic mechanism — every other approved option has a biomarker floor he does not clear. Tezepelumab is not just the default by elimination, either: NAVIGATOR showed a real 39% exacerbation reduction in patients under 150 eosinophils on their own, and 48% once its data are pooled with PATHWAY, and he has had four steroid-requiring exacerbations in the past year on maximal inhaled therapy. I would start it now rather than continue managing him on a regimen that has already failed him four times.
I want the specific subgroup data named plainly before we treat this as a straightforward start. The combination closest to his actual profile — low eosinophils AND low FeNO together, not just one or the other — showed a smaller 37% reduction in the pooled PATHWAY and NAVIGATOR analysis, with a confidence interval whose upper bound landed on 1.00 exactly. That is a real, different certainty level than the trial’s headline number. I would also want his occupational exposure history looked at more directly — diesel exhaust and irritant dust on transit days are a real confounder that has not been formally excluded.
I am not saying tezepelumab will not help him. I am saying the specific evidence for a patient with his exact biomarker combination is thinner than “it works across the spectrum” makes it sound, and that is worth being honest about before he commits to it.
Both points are real and neither one, on its own, tells us to wait. He is exacerbating actively enough that leaving him untreated while we sequentially resolve a subgroup-uncertainty question and an occupational-exposure question is its own real cost. I would start tezepelumab now, with a defined reassessment at sixteen weeks against his actual exacerbation rate rather than a biomarker proxy, and run a targeted occupational-exposure review in parallel — not before, not after, alongside.
Agreed: start tezepelumab today, with reassessment at sixteen weeks measured against his own exacerbation rate rather than any biomarker change, since none of his biomarkers were expected to move dramatically to begin with.
Agreed also: the occupational-exposure review proceeds in parallel, not sequentially — explicitly so it cannot become a reason to delay treatment while it is pending.